Prevalence of Neuroendocrine Tumors in the Gastrointestinal and Hepatobiliary Systems

Document Type : Research/Original Article

Authors

1 Echoendoscopy Unit and Department of Gastroenterology, Teknon Medical Center, Barcelona, Spain

2 Echoendoscopy Unit and Department of Gastroenterology, Hospital Sanitas CIMA, Barcelona, Spain

3 PMO, i2e3 Biomedical Research Institute, Barcelona, Spain

10.5812/acr.88004.

Abstract

Background: Carcinoid tumors are the most common neuroendocrine tumors. In recent years, these tumors have had an increase
in incidence, which is probably due to a higher number of them being incidentally found as a result of the rise of preventive
medicine.
Objectives: This study aimed to analyze a series of digestive carcinoid tumors detected by conventional endoscopy and/or echoendoscopy
to evaluate the prevalence of those located in the colon and rectum, and subsequently make a comparison with data available
in the literature.
Methods: In this retrospective, multicenter study (two centers), the clinical records of 100 white patients with more than 100 digestive
carcinoid tumors (some multiple) diagnosed from 1994 to 2018 were reviewed.
Results: The mean age of presentation was 52 years and 57% of the patients were men. The mean tumor size was 10 mm. The localization
of the tumors was: stomach 43% (n = 43); duodenum 5% (n = 5); intestine 8% (n = 8); appendix 14% (n = 14); colon 4% (n = 4);
rectum 19% (n = 19); pancreas 3% (n = 3); liver 2% (n = 2); gallbladder 1% (n = 1); primary tumor of unknown origin 1% (n = 1). Most
multifocal tumors were in the stomach (20%; n = 20), followed by the duodenum (1%; n = 1) and intestine (1%; n = 1). Metastases and
carcinoid syndrome were observed in 6% and 5% of the cases, respectively. General survival at the closure of the study was 80%.
Conclusions: Age and sex were similar to those described in the literature, while the colon and rectum represented 23% of all carcinoid
tumors. There was a predominance of gastroduodenal and rectal carcinoid tumors, probably because the series analyzed
was essentially endoscopic. In comparison with the literature, less cases of metastases or carcinoid syndrome were recorded and
survival was greater, perhaps due to earlier diagnosis and treatment.

Keywords

References

1. Oberndorfer S. Karzinoide tumoren des dünndarms. 1. Frankf Z Pathol; 1907. p. 425–32. German.
2. Sanders RJ. Carcinoids of the gastrointestinal tract. Surg Gynecol Obstet. 1964;119:369–80.
3. Macdonald RA. A study of 356 carcinoids of the gastrointestinal tract; report of four new cases of the carcinoid syndrome. Am J Med. 1956;21(6):867–78. doi: 10.1016/0002-9343(56)90101-2. [PubMed: 13372563].
4. Buchanan KD, Johnston CF, O’Hare MMT, Ardill JES, Shaw C, Collins JSA, et al. Neuroendocrine tumors: A European view. Am J Med. 1986;81(6):14–22. doi: 10.1016/0002-9343(86)90581-4.
5. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer. 2001;92(8):2204–10. doi: 10.1002/1097-0142(20011015)92:8<2204::aidcncr1564>3.0.co;2-r. [PubMed: 11596039].
6. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976;84(4):322–30. [PubMed: 961424].
7. Clemente C, Puig V, Mirada A. [Carcinoid tumor Analysis of 131 cases]. Rev Clin Esp. 1994;194:291–3. Spanish.
8. Godwin JD 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36(2):560–9. doi: 10.1002/1097-0142(197508)36:2<560::aidcncr2820360235>3.0.co;2-4. [PubMed: 1157019].
9. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813–29. doi: 10.1002/(sici)1097- 0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2. [PubMed: 9024720].
10. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. doi: 10.1200/JCO.2007.15.4377. [PubMed: 18565894].
11. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59. doi: 10.1002/cncr.11105. [PubMed: 12569593].
12. Kang H, O’Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY. Rare tumors of the colon and rectum: A national review. Int J Colorectal Dis. 2007;22(2):183–9. doi: 10.1007/s00384-006-0145-2. [PubMed: 16845516].
13. Younes RN; Grupo de Estudo de Tumores Neuroendocrinos (Getne). Neuroendocrine tumors: A registry of 1,000 patients. Rev Assoc Med Bras (1992). 2008;54(4):305–7. [PubMed: 18719787].
14. Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326(26):1721–6. doi: 10.1056/NEJM199206253262601. [PubMed: 1317506].
15. Zimmer T, Ziegler K, Liehr RM, Stolzel U, Riecken EO, Wiedenmann B. Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas.Ann N Y Acad Sci. 1994;733:425–36. doi: 10.1111/j.1749- 6632.1994.tb17292.x. [PubMed: 7978891].
16. Yoshida M, Tsukamoto Y, Niwa Y, Goto H, Hase S, Hayakawa T, et al. Endoscopic assessment of invasion of colorectal tumors with a new high-frequency ultrasound probe.Gastrointest Endosc. 1995;41(6):587– 92. [PubMed: 7672554].
17. Varas Lorenzo MJ. [Pharmacological treatment of gastroenteropancreatic apudomas with the somatostatin analog SMS 201-995 (octeotride)]. Rev Esp Enferm Dig. 1991;79:95–8. Spanish.
18. Modlin IM, Gilligan CJ, Lawton GP, Tang LH, West AB, Darr U. Gastric carcinoids. The Yale Experience. Arch Surg. 1995;130(3):250–5. discussion 255-6. doi: 10.1001/archsurg.1995.01430030020003. [PubMed: 7887791].
19. Modlin IM, Lye KD, KiddM. A 50-year analysis of 562 gastric carcinoids: Small tumor or larger problem? Am J Gastroenterol. 2004;99(1):23–32. [PubMed: 14687136].
20. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: The rapid pace of no progress. Am J Gastroenterol. 2007;102(7):1464–73. doi: 10.1111/j.1572- 0241.2007.01185.x. [PubMed: 17391319].
21. Martensson H, Nobin A, Sundler F. Carcinoid tumors in the gastrointestinal tract–an analysis of 156 cases. Acta Chir Scand. 1983;149(6):607– 16. [PubMed: 6650073].
22. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008;113(1):5–21. doi: 10.1002/cncr.23542. [PubMed: 18473355].
23. Varas Lorenzo MJ. Neuroendocrine tumors: Fascination and infrequency. Rev Esp Enferm Dig. 2009;101(3). doi: 10.4321/s1130- 01082009000300006.
24. Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–22. doi: 10.1097/01.sla.0000129342.67174.67. [PubMed: 15213627]. [PubMed Central: PMC1356383].
25. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13(12):1255–69. doi: 10.1634/theoncologist.2008-0207. [PubMed: 19091780]. [PubMed Central: PMC2901509].
26. Scherubl H. Rectal carcinoids are on the rise: Early detection by screening endoscopy. Endoscopy. 2009;41(2):162–5. doi: 10.1055/s0028-1119456. [PubMed: 19214898].
27. Kaminski MF, Polkowski M, Regula J. Prevalence and endoscopic features of rectal neuro-endocrine tumours among 50 148 participants of the Polish Colorectal-Cancer Screening Programme. Gut. 2007;56. A310.
28. Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol. 2005;17(1):1–6. [PubMed: 15608504].
29. Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RC 2nd. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009;16(1):51–60. doi: 10.1245/s10434-008-0192-8. [PubMed: 18953609].
30. Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: Between underestimation and overtreatment. World J Gastroenterol. 2009;15(18):2177–83. doi: 10.3748/wjg.15.2177. [PubMed: 19437556]. [PubMed Central: PMC2682231].
31. Varas MJ, García F, Barrios P, Borrell J. [Carcinoid tumors of the digestive system]. Med Clin. 1985;17:715–6. Spanish.
32. Varas MJ. Tumores de los islotes pancreaticos. In: Vilardell F, Rodes J, Malagelada JR, Pajares J M, Perez M, editors. Enfermedades Digestivas. 2. Madrid-Barcelona: Aula Médica; 1998. p. 1516–24. Spanish.
33. Varas Lorenzo MJ, Munoz Agel F, Espinos Perez JC, Bardaji Bofill M. [Digestive carcinoid tumors]. Rev Esp Enferm Dig. 2010;102(9):533–7. Spanish.
34. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151–60. doi: 10.1002/jso.20179. [PubMed: 15719376].
35. McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. Can J Surg. 2017;60(3):192– 7. doi: 10.1503/cjs.007616. [PubMed: 28327275]. [PubMed Central: PMC5453762]. 
36. Cesar D, Zanatto RM, da Silva MV, Golcalves R, de Mello EL, de Jesus JP. Colon and rectum neuroendocrine tumors: Experience of the National Cancer Institute in Brazil. Arq Bras Cir Dig. 2013;26(1):36–9. [PubMed: 23702868].
37. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040–4. doi: 10.1093/annonc/mdt377. [PubMed: 24050954].
38. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22(4):517–30. [PubMed: 15053292].
39. Ono A, Fujii T, Saito Y, Matsuda T, Lee DT, Gotoda T, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc. 2003;57(4):583–7. doi: 10.1067/mge.2003.142. [PubMed: 12665777].
40. Martinez-Ares D, Souto-Ruzo J, Varas Lorenzo MJ, Espinos Perez JC, Yanez Lopez J, Abad Belando R, et al. Endoscopic ultrasound-assisted endoscopic resection of carcinoid tumors of the gastrointestinal tract. Rev Esp Enferm Dig. 2004;96(12):847–55. [PubMed: 15634185].
41. Aguirre A, Cosme A, Bujanda L, Navascues JE, Larburu S, Larzabal M, et al. Diagnosis, treatment and follow-up of gastric carcinoid tumors. Analysis of 14 cases. Rev Esp Enferm Dig. 2011;103(9):493–4. [PubMed: 21951121].
42. Yuksel O. Gastric carcinoid tumors: The problems encountered in diagnosis and treatment. Int J Hematol Oncol. 2013;23(2):104–8. doi: 10.4999/uhod.10034.
43. Varas-Lorenzo MJ, Gornals JB, Munoz F, Loras C, Cruz M, Espinos JC, et al. [Gastric carcinoid tumors: An analysis of 24 cases]. Rev Esp Enferm Dig. 2013;105(10). Spanish. doi: 10.4321/s1130-01082013001000013.
44. Teleky B, Herbst F, Längle F, Neuhold N, Niederle B. The prognosis of rectal carcinoid tumours. Int J Colorectal Dis. 1992;7(1):11–4. doi: 10.1007/bf01647653.
45. Weinstock B,Ward SC, Harpaz N,Warner RR, Itzkowitz S, Kim MK. Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology. 2013;98(3):180–7. doi: 10.1159/000355612. [PubMed: 24080744].
46. Mashimo Y, Matsuda T, Uraoka T, Saito Y, Sano Y, Fu K, et al. Endoscopic submucosal resection with a ligation device is an effective and safe treatment for carcinoid tumors in the lower rectum. J Gastroenterol Hepatol. 2008;23(2):218–21. doi: 10.1111/j.1440-1746.2008.05313.x. [PubMed: 18289355].
47. Vilallonga R, Espin Basany E, Lopez Cano M, Landolfi S, Armengol Carrasco M. [Neuroendocrine carcinomas of the colon and rectum: One unit experience in six years]. Rev Esp Enferm Dig. 2008;100(1). Spanish. doi: 10.4321/s1130-01082008000100003.
48. Grin A, Streutker CJ. Neuroendocrine tumors of the luminal gastrointestinal tract. Arch Pathol Lab Med. 2015;139(6):750–6. doi: 10.5858/arpa.2014-0130-RA. [PubMed: 26030244]
Iranian Journal of Colorectal Research
Volume 7, Issue 2
June 2019
Pages 1-7

Files

Share

How to cite

Statistics